Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 7Uterine Cervical Neoplasms 4Endometrial Neoplasms 4Carcinoma, Ovarian Epithelial 4Fallopian Tube Neoplasms 3Platinum-resistant Ovarian Cancer 2Ovarian Diseases 2Neoplasms, Glandular and Epithelial 2Neoplasms by Site 2Neoplasms by Histologic Type 2Genital Neoplasms, Female 2Genital Diseases, Female 2Carcinoma 2Urogenital Neoplasms 1Platinum-resistant Recurrent Clear Cell Ovarian Cancer 1Platinum-resistant Ovarian Cancer (PROC) 1Ovarian Cancer Recurrent 1Neoplasms 1Endocrine System Diseases 1Advanced Endometrial Cancer 1Advanced Cervical Cancer 1Adnexal Diseases 1

Interventions

pembrolizumab 3lenvatinib 2Injections 2anlotinib 1Paclitaxel 1NVP-BKM120 1Gemcitabine 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Endometrial Cancer × anlotinib × Gynecologic × Clear all
NCT04574284 2025-05-28

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
170 enrolled
Gynecologic

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡